Anuska V Andjelkovic Selected Research

Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)

1/2021	Tight junctions in the blood-brain barrier promote edema formation and infarct size in stroke - Ambivalent effects of sealing proteins.
7/2014	Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anuska V Andjelkovic Research Topics

Disease

6	Stroke (Strokes) 01/2021 - 04/2007
4	Inflammation (Inflammations) 07/2014 - 11/2003
4	Reperfusion Injury 07/2014 - 06/2006
3	Central Nervous System Cavernous Hemangioma 10/2023 - 11/2015
3	Infarction (Infarctions) 01/2021 - 07/2014
3	Ischemia 11/2019 - 06/2006
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2021 - 07/2014
2	Cerebral Hemorrhage 11/2019 - 01/2018
2	Hemorrhagic Shock 01/2018 - 07/2014
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2018 - 07/2014
2	Brain Ischemia (Cerebral Ischemia) 07/2014 - 04/2007
2	Acute Lung Injury 06/2014 - 06/2013
2	Brain Edema (Cerebral Edema) 07/2010 - 04/2007
1	Glioma (Gliomas) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2022
1	Hypoxia (Hypoxemia) 01/2021
1	Edema (Dropsy) 01/2021
1	Encephalitis (Encephalitis, Rasmussen) 01/2020
1	Neuroinflammatory Diseases 01/2020
1	Hemorrhage 01/2018
1	Sepsis (Septicemia) 03/2015
1	Shock 07/2014
1	Hematoma 01/2014
1	Brain Infarction 04/2011
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2010
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 07/2010
1	Ketosis 07/2010
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 07/2008

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2018
5	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 04/2011 - 11/2003
3	Peptides (Polypeptides)IBA 01/2022 - 07/2014
3	ChemokinesIBA 01/2022 - 04/2007
3	CytokinesIBA 01/2020 - 07/2008
2	Histones (Histone)IBA 01/2019 - 03/2015
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2018 - 07/2014
1	Protein Isoforms (Isoforms)IBA 10/2023
1	Amyloid (Amyloid Fibrils)IBA 01/2022
1	LigandsIBA 01/2022
1	antiglomerular basement membrane antibodyIBA 01/2022
1	OccludinIBA 01/2021
1	SuspensionsIBA 01/2020
1	Hemostatics (Antihemorrhagics)IBA 01/2020
1	Saline SolutionIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	EnzymesIBA 01/2019
1	Claudin-1IBA 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2019
1	Connexin 43 (Connexin43)IBA 01/2018
1	Hydroxyethyl Starch Derivatives (Pentastarch)FDA Link 01/2018
1	Tight Junction ProteinsIBA 01/2018
1	CortactinIBA 11/2015
1	Fluorescein-5-isothiocyanate (FITC)IBA 03/2015
1	Junctional Adhesion Molecule AIBA 07/2014
1	Histone Deacetylase InhibitorsIBA 07/2014
1	InflammasomesIBA 06/2014
1	IronIBA 01/2014
1	zonulinIBA 06/2013
1	Antigen-Antibody Complex (Immune Complex)IBA 06/2013
1	Immunoglobulin G (IgG)IBA 06/2013
1	Nicotine FDA Link 04/2011
1	Insulin (Novolin)FDA Link 07/2010
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 07/2010
1	InterleukinsIBA 07/2008
1	isothiocyanic acidIBA 04/2007
1	Chemokine ReceptorsIBA 04/2007
1	ElectrolytesIBA 04/2007
1	AlbuminsIBA 04/2007
1	Fluorescein (Funduscein)FDA LinkGeneric 04/2007
1	Oxygen (Dioxygen)IBA 06/2006
1	Glucose (Dextrose)FDA LinkGeneric 06/2006
1	CCR2 ReceptorsIBA 11/2003

Therapy/Procedure

2	Therapeutics 11/2019 - 01/2018
2	Resuscitation 01/2018 - 07/2014
1	Radiotherapy 01/2022
1	Immunotherapy 01/2022
1	Intravenous Infusions 03/2015
1	Ligation 03/2015
1	Punctures 03/2015